Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | GOT1 | P17174 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MPO | P05164 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.52 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673296 | 0.76 | KDM4E (0.55) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL30523852 | 0.76 | KDM4E (0.55) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL17295055 | 0.74 | NPC1 (0.53) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL276918 | 0.73 | LMNA (0.52) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL18630480 | 0.73 | KDM4E (0.52) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL291003 | 0.73 | KDM4E (0.52) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL147684 | 0.73 | KDM4E (0.52) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL15835530 | 0.73 | KDM4E (0.52) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL4043089 | 0.73 | KDM4E (0.52) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL291004 | 0.73 | LMNA (0.52) | KDM4ELMNAALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-11459310-B2 | LANCL ligands | LANDOS BIOPHARMA, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| CN-114901640-A | Novel compounds useful for the treatment of dyslipidemia | 兹杜斯生命科学有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220204453-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-06-30 | — | — | US | disclosed |
| EP-4019520-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-06-29 | — | — | EP | disclosed |
| CN-114671873-A | Heterocyclic compound, organic light-emitting device including heterocyclic compound, and electronic apparatus including organic light-emitting device | 三星电子株式会社 | 2022-06-28 | — | — | CN | disclosed |
| WO-2022087146-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-10077254-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-3059233-B1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | SUMITOMO CHEMICAL CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3059233-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| EP-1678157-A4 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7456288-B2 | Heterocyclic compounds and methods of making and using thereof | REDDY US THERAPEUTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1678157-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | Reddy US Therapeutics, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-02 | — | — | US | disclosed |
| WO-2005042712-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005040163-A1 | HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE) | DR. REDDY'S LABORATORIES LTD (IN) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077254-B2 | Tetrazolinone compound and use thereof | MT-CO1, UQCRB, MT-CO2 | KDM4E 2469/4885LMNA 4024/4885ALDH1A1 1465/4885 |
| US-11459310-B2 | LANCL ligands | LANCL2, LANCL1, ACSL1 | KDM4E 3796/4885LMNA 826/4885ALDH1A1 3541/4885 |
| US-20220204453-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | CYP1A1, CYP2E1, CYP1A2 | KDM4E 3115/4885LMNA 2680/4885ALDH1A1 49/4885 |
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | PYGM, MYLK, HMOX1 | KDM4E 1840/4885LMNA 328/4885ALDH1A1 1460/4885 |
| US-20230167083-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | KDM4E 3554/4885LMNA 1134/4885ALDH1A1 4156/4885 |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MT-CO1, UQCRB, MT-CO2 | KDM4E 2469/4885LMNA 4024/4885ALDH1A1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.